Fanconi Anemia, Complementation Group E

Watchlist

(log in to enable)

Retrieved

2019-09-22

Source

Omim

Trials

—

Genes

FANCC, FANCG, BRIP1, FANCM, FANCA, FANCD2, SLX4, FANCL, RAD51C, RAD51, BRCA1, ERCC4, UBE2T, XRCC2, MAD2L2, BRCA2, FANCI, FANCF, FANCB, FANCE, PALB2, TNF, ERCC1, RFWD3, MX1, USP1, ZNF276, FAH, MUL1, POLG, CHEK1, GAS2, FAN1, PRKN, CBLL2, ATM, TP53, BLM, IFNG, FUT1, CD34, ATR, PARP1, NBN, RAD18, RUNX1, COL11A2, FAAP20, BACH1, ALDH2, SNU13, RPS19, PCNA, DLK1, H2AX, FAAP24, DCLRE1A, MRE11, NLRP2, MLH1, HPRT1, SPTAN1, RAD50, MSH2, WDR48, UCN, HES1, IL6, E2F1, PTEN, GYPA, HNF4A, HSP90AA1, COX4I1, IFNA1, IFNA13, CSF3, GH1, DCLRE1B, OCRL, NPM1, IL3, IGF1, IL1B, IL2, TP53BP1, HPGDS, TXN, SYF2, ME1, RAD51D, KAT5, TGFB1, ABL1, RB1, PRTN3, MAPK1, PPARG, SCT, XRCC3, POLD1, PMS2, RNF8, MSC, PAK1, OPRM1, PRDX6, SMARCA4, SOD2, STAT1, TERC, KITLG, MMP9, ERVW-4, UHRF1, GATA3, CASP3, OPN4, CDK1, CDC42, FAAP100, ATAD5, CTBP1, CTSB, DDX11, TIMM8A, NLN, ERCC2, MECOM, TTK, MKS1, REV1, MSH6, GGH, LOH19CR1, XRCC5, ZNF236, LEPQTL1, CPNE3, CXCR4, AIMP2, USP11, MTDH, BRAP, BMF, FAM120B, ARHGAP24, TRAF2, CUL4B, DONSON, PPM1D, USP48, CDK10, RUVBL1, FSD1L, TNFSF10, BCL2L12, ZBTB32, XRCC4, RBM45, EZR, DEL11P13, FECD3, XRCC6P5, MIR34A, TYRO3, MIR181C, UBE2B, MIR146A, GSTK1, RRDX, VCAM1, WEE1, SLCO6A1, WNT5A, CENPX, WRN, RNF168, WT1, BABAM1, XPA, ROMO1, XPC, XPO1, NDUFAF6, TLR7, NEIL1, CT55, USP16, EDIL3, SLC12A9, UIMC1, ABCC4, IKZF1, RETN, RACK1, PAG1, ATF7IP, IL17RB, AHSA1, PLK2, GINS2, RUVBL2, PPARGC1A, FSTL1, CHEK2, MCM10, DKK1, BRMS1, RNF19A, NEIL3, PARPBP, SETBP1, PTPRU, DNM1L, PHGDH, EFCAB6, MBD2, FSD1, EXO1, XPR1, ELOVL6, MAPKAPK2, GPR132, TLR8, GRAP2, WNK1, MRPL36, POLDIP2, PCBP4, ZBTB7A, TBPL1, GORASP1, PKNOX2, VPS9D1, UBL5, HDAC9, TELO2, SALL4, SH2B3, TIGAR, RECQL4, AAVS1, TPO, FXN, FOXF1, FHIT, FEN1, EZH2, ERCC5, ERBB2, EPO, EPHB2, ENO1, EIF4E, EGR1, DNA2, NQO1, DHFR, DAXX, FN1, FRA16D, CYP2B6, MTOR, GYPE, GYPB, GSTT1, GSTP1, GSTM1, GSK3B, GPX4, GOLGA4, GLRX, GFAP, GABRG1, GABRB1, XRCC6, FUS, FRZB, CYP11A1, CYP2A6, HIC1, CCNB1, RUNX3, CAV1, CAT, CASP8, BIK, BCS1L, BCR, BCL6, BAX, ATRX, AR, ALDH1A1, AFP, ADH5, ACP1, CCK, CCNE1, CTNNB1, CD33, CTNS, CSF2, MAPK14, CRK, CREBBP, ABCC2, CCR7, CLCN5, CFL1, CDKN1A, CDH1, CD68, CD48, CD44, CD38, HBG2, HIF1A, TP73, RNF4, RELA, REG1A, OPN1LW, RBBP8, RAD52, RAD51B, RAC1, PTCH1, PSMA7, PSEN1, EIF2AK2, MAPK8, PRKDC, PRKAA2, PMS1, REV3L, ATXN1, PHF1, CCL3, TOP1, TH, TERF2, ZEB1, TBX1, TAP2, SYT1, STAT5B, STAT5A, SPTBN1, SPP1, SOAT1, SLC1A3, SFRP1, SELP, PIN1, SLC25A3, HLA-DRB1, MEF2C, MCM6, MCM4, SMAD4, LRP2, LPL, STMN1, KIT, JAK2, ITGB1, INSR, INHBA, IL10, IL3RA, ICAM1, HSPA4, MECP2, MEN1, PFKFB3, MGMT, PDGFRB, CHMP1A, PAX6, NOTCH1, NME1, NCAM1, MYH4, MYH2, MTHFR, MSH3, MRC1, MMP7, MMP2, KMT2A, CIITA, PSPH

Drugs

Afatinib, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Gefitinib ( Iressa )

Afatinib, Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Gefitinib ( Iressa ), Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

A number sign (#) is used with this entry because Fanconi anemia complementation group E is caused by homozygous mutation in the FANCE gene (613976) on chromosome 6p21.

Description

Fanconi anemia (FA) is characterized by bone marrow failure, developmental abnormalities, cancer predisposition, and cellular hypersensitivity to DNA cross-linking agents such as mitomycin C (summary by de Winter et al., 2000).

For additional general information and a discussion of genetic heterogeneity of Fanconi anemia, see 227650.

Clinical Features

Joenje et al. (1995) presented evidence for a fifth subtype of Fanconi anemia, designated group E. Buchwald (1995) stated that 6 of 31 patients (12.7%) could be classified as group E. The FACE group is defined as being different from groups A (607139), B (300514), C (227645), and D (227646), and may itself be heterogeneous.

Wegner et al. (1996) also described the fifth Fanconi anemia complementation group. Their first patient, a Turkish boy, presented with psychomotor retardation, growth retardation, retarded bone age, brachycephaly, hypotelorism, epicanthus, syndactyly, brachydactyly, renal dystopia, and cryptorchidism. In addition, an asymmetric skeletal anomaly was seen with a double distal phalanx of the left thumb and hypoplasia of the right thumb. Typical hematologic features of the disorder developed at the age of 2.5 years, about 1 year after initial diagnosis. Cytogenetic studies confirmed the clinical diagnosis and revealed a spontaneous chromosomal instability and hypersensitivity to the cross-linking agents diepoxybutane and Trenimon. The findings in the patient were compared with data reported for other patients with Fanconi anemia.

Following the identification of the first FACE patient (Joenje, 1996), additional patients were identified whose cell lines complemented groups A-D. To assess their possible assignment to group E, Joenje et al. (1997) extended the complementation analysis by introducing suitable selection markers into the original FACE cell line and 3 cell lines classified as non-ABCD. The results indicated that each of these 3 cell lines represented a new complementation group, implying existence of at least 8 complementation groups in Fanconi anemia, including the 3 new groups FACF, FACG, and FACH.

Mapping

Waisfisz et al. (1999) reported the use of homozygosity mapping and genetic linkage analysis to map the FANCE locus to 6p22-p21 in an interval of 18.2 cM flanked by markers D6S422 and D6S1610. Three small families were assigned to group FA-E by cell fusion and complementation analysis. Studies showed that data from even a small number of families can be successfully used to map a gene for a genetically heterogeneous disorder. At that time, 4 of the 8 known complementation groups had been mapped to specific sites and the specific gene had been isolated in the case of 3.

Molecular Genetics

In 3 patients with Fanconi anemia, 2 from Turkey and 1 from Bangladesh, de Winter et al. (2000) identified homozygous mutations in the FANCE gene (613976.0001-613976.0003).